Low-density-lipoprotein apheresis-mediated endothelial activation therapy to severe-peripheral artery disease study: Rationale and study design.
dextran sulfate cellulose column
endothelial function
lipoprotein apheresis
normal cholesterol
peripheral arterial disease
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
30
12
2019
revised:
05
02
2020
accepted:
05
02
2020
pubmed:
12
6
2020
medline:
15
9
2021
entrez:
12
6
2020
Statut:
ppublish
Résumé
A novel approach is required for standard therapy-resistant peripheral arterial disease (PAD). This is a single-center, single-arm, interventional study (LDL Apheresis-Mediated Endothelial Activation Therapy to Severe-Peripheral Artery Disease study), which aims to evaluate the efficacy and safety of lipoprotein apheresis (LA) with a dextran sulfate cellulose column in PAD with controlled serum cholesterol levels. The study participants have standard therapy-resistant PAD with controlled serum cholesterol levels. A total of 35 patients undergo 10 sessions of LA therapy. The ankle-brachial index and vascular quality of life questionnaire are assessed before and after the treatment period as primary outcomes. Registration of patients began in November 2015 and is planned to be concluded in October 2020.
Identifiants
pubmed: 32524727
doi: 10.1111/1744-9987.13546
doi:
Substances chimiques
Cholesterol, LDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
524-529Subventions
Organisme : Strategic PRomotion for practical application of INnovative medical Technology
Organisme : The Translational Research program
Organisme : Japan Agency for Medical Research and Development (AMED)
Organisme : Yokohama City University research grant "KAMOME Project"
Organisme : Strategic Research Project of Yokohama City University
Organisme : The Cardiovascular Research Fund
Organisme : Salt Science Research Foundation
Organisme : Banyu Life Science Foundation International
Organisme : SENSHIN Medical Research Foundation
Organisme : Japan Society for the Promotion of Science
Organisme : Kanae Foundation for the Promotion of Medical Science
Organisme : Uehara Memorial Foundation grant
Organisme : Yokohama Foundation for Advancement of Medical Science
Informations de copyright
© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Almasri J, Adusumalli J, Asi N, et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. J Vasc Surg. 2018;68:624-633.
Klein AJ, Ross CB. Endovascular treatment of lower extremity peripheral arterial disease. Trends Cardiovasc Med. 2016;26:495-512.
Wang A, Richhariya A, Gandra SR, et al. Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc. 2016;5:e003294.
Agishi T, Kitano Y, Suzuki T, et al. Improvement of peripheral circulation by low density lipoprotein adsorption. ASAIO Trans. 1989;35:349-351.
Tsuchida H, Shigematsu H, Ishimaru S, Iwai T, Akaba N, Umezu S. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral arterial disease LDL apheresis multicenter study (P-LAS). Int Angiol. 2006;25:287-292.
Stefanutti C, Vivenzio A, Ferraro PM, Morozzi C, Belotherkovsky D. Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias. Cytokine. 2011;56:835-841.
Otto C, Geiss HC, Empen K, Parhofer KG. Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis. 2004;174:151-156.
van Wijk DF, Sjouke B, Figueroa A, et al. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol. 2014;64:1418-1426.
Hara T, Kiyomoto H, Hitomi H, et al. Low-density lipoprotein apheresis for haemodialysis patients with peripheral arterial disease reduces reactive oxygen species production via suppression of NADPH oxidase gene expression in leucocytes. Nephrol Dial Transplant. 2009;24:3818-3825.
Kopprasch S, Bornstein SR, Bergmann S, Graessler J, Julius U. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters-A comparison of two different apheresis techniques. Atheroscler Suppl. 2015;18:80-84.
Tsurumi-Ikeya Y, Tamura K, Azuma K, et al. Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients. Arterioscler Thromb Vasc Biol. 2010;30:1058-1065.
Morimoto S, Yano Y, Maki K, Sawada K, Iwasaka T. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Am J Nephrol. 2007;27:643-648.
Tamura K, Tsurumi-Ikeya Y, Wakui H, et al. Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease. Ther Apher Dial. 2013;17:185-192.
Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the vascular quality of life questionnaire: A new disease-specific quality of life measure for use in lower limb ischemia. J Vasc Surg. 2001;33:679-687.
Matsui Y, Furue M, Sanada H, et al. Development of the DESIGN-R with an observational study: An absolute evaluation tool for monitoring pressure ulcer wound healing. Wound Repair Regen. 2011;19:309-315.
Conijn AP, Jonkers W, Rouwet EV, Vahl AC, Reekers JA, Koelemay MJW. Introducing the concept of the minimally important difference to determine a clinically relevant change on patient-reported outcome measures in patients with intermittent claudication. Cardiovasc Intervent Radiol. 2015;38:1112-1118.
Frans FA, Nieuwkerk PT, Met R, et al. Statistical or clinical improvement? Determining the minimally important difference for the vascular quality of life questionnaire in patients with critical limb ischemia. J Geophys Res Biogeosci. 2014;47:180-186.
Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257-1264.
Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: A meta-analysis. JAMA. 2008;300:197-208.
Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral artery disease: Past, present, and future. Am J Med. 2019;132:1133-1141.
Yamaguchi T, Miyata T, Ichiki M, et al. Reliability and validity of the Japanese version of the vascular quality of life (VascuQOL) questionnaire. J Jpn Coll Angiol. 2011;51:347-358.
Brunelli E, La Russa D, Pellegrino D. Impaired oxidative status is strongly associated with cardiovascular risk factors. Oxid Med Cell Longev. 2017;2017:6480145.